RxDoctor Payments Data

Abdullah Alshammaa, MD

Neurology · East Lansing, MINPI 1073908869

Payments from drug & device makers

$1,390in general payments, 2019–2025

Across 32 payments — averaging $43.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$446
  • Neurelis, Inc.$194
  • Eisai Inc.$162
  • Neuropace, Inc.$152
  • SK Life Science, Inc.$145
  • Livanova USA, Inc.$136
  • plus $154 from 7 others

What the payments were for

  • Food & beverage$1,390100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,390 in reported general payments places this provider in the 50th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$46,008
Medicare patients
258
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam15$20,789
Emgality PenGalcanezumab-Gnlm22$14,899
UbrelvyUbrogepant11$10,798
Lacosamide31$1,278
Divalproex Sodium12$1,068
Levetiracetam18$1,054
Topiramate34$774
Zonisamide17$658
Carbidopa-LevodopaCarbidopa/Levodopa15$625
Primidone23$600
Gabapentin30$571
Tizanidine Hcl13$345
Pregabalin38$309
Lamotrigine24$272
Donepezil Hcl23$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$446$20,78915 claims
AbbVieUbrelvy$15$10,79811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 652 neurology providers in Michigan.

Other neurology in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →